Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.

@article{Rossignol2011EplerenoneSB,
  title={Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.},
  author={Patrick Rossignol and Jo{\"e}l M{\'e}nard and Renaud Fay and Finn Gustafsson and Bertram Pitt and Fa{\"i}ez Zannad},
  journal={Journal of the American College of Cardiology},
  year={2011},
  volume={58 19},
  pages={1958-66}
}
OBJECTIVES The purpose of this study was to determine whether a diuretic effect may be detectable in patients treated with eplerenone, a mineralocorticoid receptor antagonist, as compared with placebo during the first month of EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study) (n = 6,080) and whether this was associated with eplerenone's beneficial effects on cardiovascular outcomes. BACKGROUND The mechanism of the survival benefit of eplerenone in… CONTINUE READING